An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM). In the present phase 2, multicenter, open-labe...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Vij, Ravi, Wang, Michael, Kaufman, Jonathan L., Lonial, Sagar, Jakubowiak, Andrzej J., Stewart, A. Keith, Kukreti, Vishal, Jagannath, Sundar, McDonagh, Kevin T., Alsina, Melissa, Bahlis, Nizar J., Reu, Frederic J., Gabrail, Nashat Y., Belch, Andrew, Matous, Jeffrey V., Lee, Peter, Rosen, Peter, Sebag, Michael, Vesole, David H., Kunkel, Lori A., Wear, Sandra M., Wong, Alvin F., Orlowski, Robert Z., Siegel, David S.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2012
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123327/
https://ncbi.nlm.nih.gov/pubmed/22555973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-03-414359
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker